Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities

References

• SoveriniSDe BenedittisCManciniMMartinelliGBest practices in chronic myeloid leukemia monitoring and managementOncologist201621562663327032870
   PubMed Web of Science ®Google Scholar
• GoldmanJMChronic myeloid leukemia: a historical perspectiveSemin Hematol201047430231120875546
   PubMed Web of Science ®Google Scholar
• DeiningerMWGoldmanJMMeloJVThe molecular biology of chronic myeloid leukemiaBlood200096103343335611071626
   PubMed Web of Science ®Google Scholar
• BrunsICzibereAFischerJCThe hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescenceLeukemia200923589289919158832
   PubMed Web of Science ®Google Scholar
• ShetASJahagirdarBNVerfaillieCMChronic myelogenous leukemia: mechanisms underlying disease progressionLeukemia20021681402141112145676
   PubMed Web of Science ®Google Scholar
• ŻołnierowiczJKawiakJHoserGPathogenesis of chronic myeloid leukemia – from gene to targeted therapyHematologia20101195218
   Google Scholar
• MarleySBGordonMYChronic myeloid leukaemia: stem cell derived but progenitor cell drivenClin Sci (Lond)20051091132515966868
   PubMed Web of Science ®Google Scholar
• PerrottiDJamiesonCGoldmanJSkorskiTChronic myeloid leukemia: mechanisms of blastic transformationJ Clin Invest201012072254226420592475
   PubMed Web of Science ®Google Scholar
• ArberDAOraziAHasserjianRThe 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood2016127202391240527069254
   PubMed Web of Science ®Google Scholar
• BaccaraniMDeiningerMWRostiGEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood2013122687288423803709
   PubMed Web of Science ®Google Scholar
• HehlmannRHow I treat CML blast crisisBlood2012120473774722653972
   PubMed Web of Science ®Google Scholar
• HasfordJBaccaraniMHoffmannVPredicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreBlood2011118368669221536864
   PubMed Web of Science ®Google Scholar
• SachaTLewandowskiKHellmannAPolish adult leukemia Group recommendations for diagnosis and treatment of chronic myeloid leukemia in 2013Acta Haematol Pol201344345362
   Google Scholar
• MűllerMThe role of second-generation TKIs as first-line treatments in CMLEXcel Preceptorship Interactive Forum on CML916–172013Mannheim, GermanyUniversity Medical Center2013
   Google Scholar
• GongZMedeirosLJCortesJECytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapyBlood Adv20171262541255229296906
   PubMed Web of Science ®Google Scholar
• WangWCortesJETangGRisk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyBlood2016127222742275027006386
   PubMed Web of Science ®Google Scholar
• JabbourECortesJNazhaAEUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experienceBlood2012119194524452622431574
   PubMed Web of Science ®Google Scholar
• LarsonRAHochhausAHughesTPNilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year followupLeukemia201226102197220322699418
   PubMed Web of Science ®Google Scholar
• KantarjianHMShahNPCortesJEDasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year followup from a randomized phase 3 trial (DASISION)Blood201211951123112922160483
   PubMed Web of Science ®Google Scholar
• SachaTSzmitSZozulińska-ZiółkiewiczDPrejznerWGóra-TyborJRecommendations for assessment of co-morbidities and tyrosine kinase inhibitor choice in patients suffering from chronic myeloid leukemiaActa Haemat Pol201647184196
   Google Scholar
• SuredaABaderPCesaroSIndications for allo-and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015Bone Marrow Transplant20155081037105625798672
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [homepage on the Internet]NCCN clinical practice guidelines in oncologyCML Version22017 Available from: www.nccn.orgAccessed February, 2018
   Google Scholar
• KhouryHJCortesJBaccaraniMOmacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitorsLeuk Lymphoma201556112012724650054
   PubMed Web of Science ®Google Scholar
• PavlůJApperleyJFAllogeneic stem cell transplantation for chronic myeloid leukemiaCurr Hematol Malig Rep201381435123275177
   PubMed Web of Science ®Google Scholar
• SaglioGHochhausAGohYTDasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of followup in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice dailyCancer2010116163852386120564086
   PubMed Web of Science ®Google Scholar
• HughesTDeiningerMHochhausAMonitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood20061081283716522812
   PubMed Web of Science ®Google Scholar
• MarinDHedgleyCClarkREPredictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinibBlood2012120229129422645182
   PubMed Web of Science ®Google Scholar
• ChenZMedeirosLJKantajianHMDifferential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemiaBlood Cancer J201772e52128157214
   PubMed Web of Science ®Google Scholar
• MahonFXRichterJGuilhotJInterim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI studyBlood201412415124993879
   PubMed Web of Science ®Google Scholar
• ReaDNicoliniFETulliezMDiscontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI studyBlood2017129784685427932374
   PubMed Web of Science ®Google Scholar
• DESTINY (De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel) study. ASH. 2016; Abstract 938.
   Google Scholar
• Chávez-GonzálezAAvilés-VázquezSMoreno-LorenzanaDMayaniHHematopoietic stem cells in chronic myeloid leukemia. Chapter 8Stem Cell Biology in Normal Life and DiseasesStem UKKamran Alimoghaddam, IntechOpen2013
   Google Scholar
• CardoneMHRoyNStennickeHRRegulation of cell death protease caspase-9 by phosphorylationScience19982825392131813219812896
   PubMed Web of Science ®Google Scholar
• SteelmanLSPohnertSCSheltonJGFranklinRABertrandFEMcCubreyJAJAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesisLeukemia200418218921814737178
   PubMed Web of Science ®Google Scholar
• DemingPBSchaferZTTashkerJSPottsMBDeshmukhMKornbluthSBCR-ABL-mediated protection from apoptosis downstream of mitochondrial cytochrome c releaseMol Cell Biol20042423102891029915542838
   PubMed Web of Science ®Google Scholar
• Antoszewska-SmithJPawlowskaEBlasiakJReactive oxygen species in BCR-ABL1-expressing cells – relevance to chronic myeloid leukemiaActa Biochim Pol201764111027904889
   PubMed Web of Science ®Google Scholar
• SallmyrAFanJRassoolFVGenomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repairCancer Lett200827011918467025
   PubMed Web of Science ®Google Scholar
• DuevaRIliakisGAlternative pathways of non-homologous end joining (NHEJ) in genomic instability and cancerTransl Cancer Res20132163177
   Web of Science ®Google Scholar
• MuvarakNKelleySRobertCC-myc generates repair errors via increased transcription of alternative-NHEJ factors, LIG3 and PARP1, in tyrosine kinase-activated leukemiasMol Cancer Res201513469971225828893
   PubMed Web of Science ®Google Scholar
• WhiteEDiPaolaRSThe double-edged sword of autophagy modulation in cancerClin Cancer Res200915175308531619706824
   PubMed Web of Science ®Google Scholar
• HuYLiuJWuYFmTOR and autophagy in regulation of acute lung injury: a review and perspectiveMicrobes Infect201416972773425084494
   PubMed Web of Science ®Google Scholar
• AltmanBJRathmellJCMetabolic stress in autophagy and cell death pathwaysCold Spring Harb Perspect Biol201249a00876322952396
   PubMed Web of Science ®Google Scholar
• MacintoshRLRyanKMAutophagy in tumour cell deathSemin Cancer Biol201323534435123774296
   PubMed Web of Science ®Google Scholar
• ShengZMaLSunJEZhuLJGreenMRBCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcriptionBlood2011118102840284821715304
   PubMed Web of Science ®Google Scholar
• RamosEKHoffmannADGersonSLLiuHNew opportunities and challenges to defeat cancer stem cellsTrends Cancer201731178079629120754
   PubMed Web of Science ®Google Scholar
• SkorskiTChronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease stateLeuk Lymphoma201152Suppl 1232921299457
   PubMed Web of Science ®Google Scholar
• XinPLiCZhengYEfficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell linesDrug Des Devel Ther20171111151126
   PubMed Web of Science ®Google Scholar
• SchusterKZhengJArbiniAAZhangCCScaglioniPPSelective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivoBlood Cancer J2011149e34
   Web of Science ®Google Scholar
• LuZXuNHeBInhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemiaJ Exp Clin Cancer Res20173614328283035
   PubMed Web of Science ®Google Scholar
• SinclairALatifALHolyoakeTLTargeting survival pathways in chronic myeloid leukaemia stem cellsBr J Pharmacol201316981693170723517124
   PubMed Web of Science ®Google Scholar
• ArakawaSHondaSYamaguchiHShimizuSMolecular mechanisms and physiological roles of Atg5/Atg7-independent alternative autophagyProc Jpn Acad Ser B Phys Biol Sci2017936378385
   PubMed Web of Science ®Google Scholar
• BellodiCLidonniciMRHamiltonATargeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cellsJ Clin Invest200911951109112319363292
   PubMed Web of Science ®Google Scholar
• OkabeSTauchiTKatagiriSTanakaYOhyashikiKCombination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cellsJ Hematol Oncol201473724775308
   PubMed Web of Science ®Google Scholar
• GallipoliPCookARhodesSJAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivoBlood201412491492150124957147
   PubMed Web of Science ®Google Scholar
• YehYYLiouJPLeeYLLinJYHuangHMMPT0B002, a novel microtubule inhibitor, downregulates T315I mutant BCR-ABLl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cellsInvest New Drugs201735442743528349229
   PubMed Web of Science ®Google Scholar
• HeidelFHBullingerLFengZGenetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CMLCell Stem Cell201210441242422482506
   PubMed Web of Science ®Google Scholar
• ZhouHMakPYMuHCombined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivoLeukemia201731102065207428321124
   PubMed Web of Science ®Google Scholar
• CayssialsEGuilhotFBeyond tyrosine kinase inhibitors: combinations and other agentsBest Pract Res Clin Haematol201629327128327839568
   PubMed Web of Science ®Google Scholar
• KataokaKKurokawaMEcotropic viral integration site 1, stem cell self-renewal and leukemogenesisCancer Sci201210381371137722494115
   PubMed Web of Science ®Google Scholar
• SatoTGoyamaSKataokaKEVI1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemiaOncogene201433425028503824747972
   PubMed Web of Science ®Google Scholar
• ZhaoCChenAJamiesonCHHedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemiaNature2009458723977677919169242
   PubMed Web of Science ®Google Scholar
• IrvineDAZhangBKinstrieRDeregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemiaSci Rep201662547627157927
   PubMed Web of Science ®Google Scholar
• AsimakopoulosFAShteperPJKrichevskySABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemiaBlood19999472452246010498618
   PubMed Web of Science ®Google Scholar
• WangZYuanHRothMSIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cellsOncogene201332558959822410779
   PubMed Web of Science ®Google Scholar
• ArrigoniEDel ReMGalimbertiSConcise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatmentStem Cells Transl Med20187330531429418079
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSCortesJResults of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaCancer200398352252812879469
   PubMed Web of Science ®Google Scholar
• JinYZhouJXuFTargeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemiaJ Clin Invest2016126103961398027643437
   PubMed Web of Science ®Google Scholar
• KoschmiederSVetrieDEpigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic optionsSemin Cancer Biol20185118019728778403
   PubMed Web of Science ®Google Scholar
• MassiminoMStellaSTirròENon ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemiaMol Cancer20181715629455672
   PubMed Web of Science ®Google Scholar
• ScottMTKorfiKSaffreyPEpigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibitionCancer Discov20166111248125727630125
   PubMed Web of Science ®Google Scholar
• PetersonLFMitrikeskaEGiannolaDp53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cellsLeukemia201125576176921350558
   PubMed Web of Science ®Google Scholar
• CarterBZMakPYMuHCombined targeting of Bcl-2 and Bcr-Abl tyrosine kinase eradicates chronic myeloid leukemia stem cellsSci Transl Med20168355355ra117
   PubMed Web of Science ®Google Scholar
• GoffDJCourt RecartASadaranganiAA Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibitionCell Stem Cell201312331632823333150
   PubMed Web of Science ®Google Scholar
• KoTKChuahCTHuangJWNgKPOngSTThe BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitorsOncotarget20145199033903825333252
   PubMed Web of Science ®Google Scholar
• GontarewiczABalabanovSKellerGSimultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant Bcr-Abl mutations including T315IBlood200811184355436418268096
   PubMed Web of Science ®Google Scholar